|
||||||||||||||||||||||||||
| SEC Info℠ | | | Home | | | Search | | | My Interests | | | Help | | | Sign In | | | Please Sign In | |||||||
|
||||||||||||||||||||||||||
As Of Filer Filing For·On·As Docs:Size Issuer Filing Agent 4/01/24 AIM ImmunoTech Inc. 10-K 12/31/23 84:8.7M M2 Compliance LLC/FA |
Document/Exhibit Description Pages Size
1: 10-K Annual Report HTML 2.15M
2: EX-4.25 Instrument Defining the Rights of Security Holders HTML 37K
3: EX-10.104 Material Contract HTML 187K
4: EX-10.105 Material Contract HTML 103K
5: EX-21.1 Subsidiaries List HTML 23K
6: EX-23.1 Consent of Expert or Counsel HTML 23K
11: EX-97.1 Clawback Policy re: Recovery of Erroneously HTML 34K
Awarded Compensation
7: EX-31.1 Certification -- §302 - SOA'02 HTML 29K
8: EX-31.2 Certification -- §302 - SOA'02 HTML 29K
9: EX-32.1 Certification -- §906 - SOA'02 HTML 25K
10: EX-32.2 Certification -- §906 - SOA'02 HTML 25K
17: R1 Cover HTML 94K
18: R2 Consolidated Balance Sheets HTML 116K
19: R3 Consolidated Balance Sheets (Parenthetical) HTML 50K
20: R4 Consolidated Statements of Operations and HTML 91K
Comprehensive Loss
21: R5 Consolidated Statements of Changes in HTML 59K
Stockholders' Equity
22: R6 Consolidated Statements of Cash Flows HTML 107K
23: R7 Description of Business HTML 37K
24: R8 Summary of Significant Accounting Policies HTML 64K
25: R9 Marketable Investments HTML 47K
26: R10 Patents and Trademark Rights, Net HTML 52K
27: R11 Accrued Expenses HTML 32K
28: R12 Stockholders? Equity HTML 351K
29: R13 Segment and Related Information HTML 30K
30: R14 Research, Consulting and Supply Agreements HTML 64K
31: R15 401(k) Plan HTML 29K
32: R16 Employment Agreements HTML 52K
33: R17 Leases HTML 49K
34: R18 Income Taxes (FASB ASC 740 Income Taxes) HTML 65K
35: R19 Certain Relationships and Related Transactions HTML 29K
36: R20 Concentrations of Risk HTML 29K
37: R21 Fair Value HTML 75K
38: R22 Contingencies HTML 30K
39: R23 Subsequent Events HTML 31K
40: R24 Summary of Significant Accounting Policies HTML 96K
(Policies)
41: R25 Summary of Significant Accounting Policies HTML 30K
(Tables)
42: R26 Marketable Investments (Tables) HTML 43K
43: R27 Patents and Trademark Rights, Net (Tables) HTML 52K
44: R28 Accrued Expenses (Tables) HTML 31K
45: R29 Stockholders? Equity (Tables) HTML 305K
46: R30 Leases (Tables) HTML 44K
47: R31 Income Taxes (FASB ASC 740 Income Taxes) (Tables) HTML 55K
48: R32 Fair Value (Tables) HTML 54K
49: R33 Schedule of Property and Equipment (Details) HTML 31K
50: R34 Summary of Significant Accounting Policies HTML 42K
(Details Narrative)
51: R35 Schedule of Available of Sale (Details) HTML 33K
52: R36 Schedule of Equity Securities (Details) HTML 30K
53: R37 Marketable Investments (Details Narrative) HTML 25K
54: R38 Schedule of Patent and Trademark Rights (Details) HTML 36K
55: R39 Schedule of Changes in Patents, Trademark Rights HTML 32K
(Details)
56: R40 Schedule of Amortization of Patents and Trademarks HTML 39K
(Details)
57: R41 Patents and Trademark Rights, Net (Details HTML 29K
Narrative)
58: R42 Schedule of Accrued Expenses (Details) HTML 33K
59: R43 Schedule of Options and Equity Estimated Based on HTML 37K
Weighted Average Assumptions (Details)
60: R44 Schedule of Stock Option Activity (Details) HTML 92K
61: R45 Schedule of Vest Stock Option Activity (Details) HTML 100K
62: R46 Schedule of Unvested Stock Option Activity HTML 77K
(Details)
63: R47 Schedule of Warrants Outstanding and Exercisable HTML 72K
(Details)
64: R48 Stockholders? Equity (Details Narrative) HTML 207K
65: R49 Segment and Related Information (Details HTML 25K
Narrative)
66: R50 Research, Consulting and Supply Agreements HTML 80K
(Details Narrative)
67: R51 401(k) Plan (Details Narrative) HTML 31K
68: R52 Employment Agreements (Details Narrative) HTML 55K
69: R53 Schedule of AIM Recognized Rent Expense Associated HTML 34K
with Operating Lease (Details)
70: R54 Schedule of Operating Lease Future Payments HTML 37K
(Details)
71: R55 Leases (Details Narrative) HTML 41K
72: R56 Schedule of Components of Net Deferred Tax Assets HTML 46K
and Liabilities (Details)
73: R57 Schedule of Effective Tax Rate and Statutory Tax HTML 91K
Rate (Details)
74: R58 Income Taxes (FASB ASC 740 Income Taxes) (Details HTML 39K
Narrative)
75: R59 Schedule of Assets and Liabilities Measured at HTML 36K
Fair Value on a Recurring Basis (Details)
76: R60 Schedule of Assumptions to Estimate Fair Value of HTML 41K
Warrants (Details)
77: R61 Schedule of Range of Probabilities (Details) HTML 31K
78: R62 Fair Value (Details Narrative) HTML 35K
79: R63 Subsequent Events (Details Narrative) HTML 41K
81: XML IDEA XML File -- Filing Summary XML 139K
84: XML XBRL Instance -- form10-k_htm XML 1.81M
80: EXCEL IDEA Workbook of Financial Report Info XLSX 140K
13: EX-101.CAL Inline XBRL Taxonomy Extension Calculation XML 210K
Linkbase Document -- aim-20231231_cal
14: EX-101.DEF Inline XBRL Taxonomy Extension Definition Linkbase XML 669K
Document -- aim-20231231_def
15: EX-101.LAB Inline XBRL Taxonomy Extension Label Linkbase XML 1.22M
Document -- aim-20231231_lab
16: EX-101.PRE Inline XBRL Taxonomy Extension Presentation XML 920K
Linkbase Document -- aim-20231231_pre
12: EX-101.SCH Inline XBRL Taxonomy Extension Schema Document -- XSD 177K
aim-20231231
82: JSON XBRL Instance as JSON Data -- MetaLinks 484± 706K
83: ZIP XBRL Zipped Folder -- 0001493152-24-012058-xbrl Zip 482K
Exhibit 23.1
Consent of Independent Registered Public Accounting Firm
We hereby consent to the incorporation by reference in the Registration Statements on Form S-3 (No. 333-262280), Form S-1 (No. 333-217671, 333-220756, 333-226057, 333-229051 and 333-233657) and Form S-8 (No. 333-257614, 333-160499, 333-209060, 333-220296, 333-227543 and 333-240315) of AIM ImmunoTech, Inc. (the Company) of our report dated March 29, 2024, relating to the consolidated financial statements which appears in this Annual Report on Form 10-K.
| /s/ BDO USA, P.C. |
Miami, Florida
| This ‘10-K’ Filing | Date | Other Filings | ||
|---|---|---|---|---|
 | ||||
| Filed as of: | 4/1/24 | None on these Dates | ||
| Filed on: | 3/29/24 | |||
| For Period end: | 12/31/23 | |||
| List all Filings | ||||
As Of Filer Filing For·On·As Docs:Size Issuer Filing Agent 5/15/24 AIM ImmunoTech Inc. 10-Q 3/31/24 75:5.3M M2 Compliance LLC/FA 5/01/24 AIM ImmunoTech Inc. 424B5 1:260K M2 Compliance LLC/FA 4/19/24 AIM ImmunoTech Inc. S-1 6:628K M2 Compliance LLC/FA |